Bio-Rad (BIO) Q2 2025: Process Chromatography Jumps 25%, Offsetting Academic Market Drag
Process chromatography sales surged in Q2, allowing Bio-Rad to raise its full-year outlook despite persistent weakness in academic research and Chinese diagnostics. Margin expansion was driven by tariff relief, disciplined cost actions, and a more resilient consumables base. Investors should focus on the sustainability of process chromatography demand and the integration of Stilla Technologies, as both will shape the company’s trajectory into 2026.
Summary
- Process Chromatography Outpaces Expectations: Customer demand pulled forward, driving a 25% YoY jump and lifting full-year guidance.
- Margin Expansion Driven by Tariff Relief: Lower tariff headwinds and disciplined cost control enabled operating margin guidance to rise 200bps.
- Portfolio Evolution Accelerates: Stilla Technologies acquisition and new DDPCR launches position Bio-Rad for market share gains in digital PCR.
Performance Analysis
Bio-Rad delivered a solid Q2 with net sales of $652 million, up 2.1% YoY, as robust process chromatography demand offset continued softness in academic research and China diagnostics. Life Sciences revenue grew 4.9% YoY, propelled by double-digit process chromatography gains, while core life sciences (excluding process chromatography) declined 3.7%, highlighting ongoing headwinds in biotech and academic research. Clinical Diagnostics remained flat, with international growth offsetting lower China sales due to diabetes testing reimbursement cuts.
Gross margin compressed slightly to 53.7% (non-GAAP), reflecting higher material costs and lower fixed cost absorption as instrument demand remained subdued. SG&A expense rose due to higher variable compensation, while R&D spend ticked up on project investments. Operating margin, however, outperformed on the back of cost controls and reduced tariff pressure. Free cash flow conversion remained strong at 117% YTD, and the company executed $139 million in share repurchases in Q2, signaling capital allocation discipline.
- Process Chromatography Pull-Forward: About 20% of Q2 process chromatography sales were advanced from future quarters, but management expects low double-digit growth for the full year, up from prior high single-digit guidance.
- Consumables Resilience: Droplet digital PCR (DDPCR) consumables grew high single digits, cushioning against weak instrument sales and validating the company’s focus on recurring revenue streams.
- China Diagnostics Still Soft: No new reimbursement headwinds emerged beyond diabetes, but overall China demand remains tepid, with volume-based procurement (VBP) not impacting Bio-Rad’s portfolio.
Bio-Rad’s margin strength and improved cash flow are clear positives, but the company remains exposed to macro and funding volatility, especially in academic and Chinese markets.
Executive Commentary
"Our clinical diagnostics business remains stable, while our life science segment benefited from the strength in our process chromatography portfolio. Product mix and a continued focus on cost control and discretionary spending helped drive an outperformance in operating margin for the quarter."
John DiVincenzo, President and Chief Operating Officer
"Reflecting the easing of trade tensions with China and delays in implementing tariffs in other regions, we now expect a reduced headwind of approximately 30 to 40 basis points to operating margin."
Rupe Lacaraju, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. Process Chromatography as Growth Engine
Process chromatography, used for purifying biomolecules in biopharma manufacturing, delivered a standout quarter with a 25% YoY increase. Management attributed part of this to customer order pull-forwards, but also signaled a normalization of demand as inventory overhangs clear. The full-year outlook was raised to low double-digit growth, suggesting sustained demand and a larger addressable market. This segment’s momentum is now central to offsetting cyclical weakness in research instruments.
2. DDPCR Portfolio Expansion and Stilla Integration
Droplet digital PCR (DDPCR), a technology for ultra-sensitive nucleic acid quantification, is a strategic pillar for Bio-Rad. The Q2 closing of the Stilla Technologies acquisition and launch of the QX700 series expands the portfolio, targeting both simplified workflows and high-throughput needs. Early customer feedback is positive, and management expects mid-single-digit growth in DDPCR revenue for 2025, up from low single-digit prior guidance. The company is positioning DDPCR as an alternative to qPCR and next-gen sequencing in clinical and research markets.
3. Margin Management Amid Volatility
Operating margin guidance was raised by 200bps to 12-13%, driven by sharply reduced tariff headwinds (now 30-40bps versus 130bps previously), improved manufacturing absorption, and stable product mix. Management has actively shifted supply chains and manufacturing to adapt to evolving trade policies, while maintaining flexibility to respond to future tariff changes. Cost discipline remains a recurring theme, with SG&A and R&D spending tightly managed relative to revenue growth.
4. Diagnostics Stability and China Risk Management
Diagnostics, Bio-Rad’s legacy business supplying clinical labs, remains steady outside China, with rest-of-world markets growing 0.7%. In China, volume-based procurement and DRG policy changes have not materially impacted the business beyond already-absorbed diabetes testing reimbursement cuts. Specialty diagnostics and quality controls, which are less affected by reimbursement, provide some insulation. However, management continues to monitor the evolving policy landscape closely.
5. Capital Allocation and Shareholder Returns
Bio-Rad remains committed to capital discipline, generating robust free cash flow and returning capital via share buybacks. With $337 million still authorized for repurchases, the company retains flexibility for further buybacks or strategic investments. The decision to postpone Investor Day to spring 2026 signals a cautious approach amid continued market and geopolitical volatility.
Key Considerations
Bio-Rad’s Q2 reflects a business balancing near-term volatility with long-term portfolio evolution. Investors should weigh the following:
- Process Chromatography Sustainability: Pull-forward demand boosted Q2, but full-year guidance implies underlying demand remains robust as inventory corrections abate.
- DDPCR Platform Integration: Stilla Technologies’ integration and new product launches are critical for capturing share in the growing digital PCR market, but instrument demand remains a weak spot.
- China Diagnostics Exposure: While VBP and DRG policies have not yet impacted Bio-Rad beyond diabetes testing, China remains a risk given ongoing reimbursement and funding pressures.
- Margin Levers and Tariff Sensitivity: Margin expansion is heavily reliant on reduced tariff headwinds and cost actions; any reversal could pressure profitability.
- Academic and Biotech Funding Volatility: Instrument demand is still subdued, and any further deterioration in research funding could weigh on growth outside of consumables.
Risks
Bio-Rad faces ongoing risks from macroeconomic uncertainty, especially in academic and Chinese markets where funding and reimbursement remain volatile. Tariff policy remains a swing factor for margin, and any resurgence in trade tensions could reverse recent gains. Integration of Stilla Technologies must deliver on growth and synergy expectations to justify the investment and expanded portfolio. Finally, any slowdown in process chromatography or consumables demand could expose the company to renewed top-line and margin pressure.
Forward Outlook
For Q3 2025, Bio-Rad expects:
- Revenue and margin trends similar to Q2, with Q4 seasonality driving a step-up in both metrics.
- Continued strong process chromatography and DDPCR consumables demand, with instrument sales remaining soft.
For full-year 2025, management raised guidance:
- Total currency-neutral revenue now flat to up 1% (midpoint raised 25bps).
- Life Sciences revenue expected flat to up 1% (prior: flat to down 3%).
- DDPCR revenue growth revised to mid-single digits (prior: low single digits).
- Operating margin raised to 12-13% (prior: 10-12%).
Management cited reduced tariff headwinds, improved process chromatography visibility, and more resilient consumables as key tailwinds. The company will continue to monitor academic, biotech, and China market dynamics closely.
- Tariff and supply chain flexibility remain under active management.
- Investor Day postponed to spring 2026 due to market volatility.
Takeaways
Bio-Rad’s Q2 demonstrates the importance of portfolio diversity and operational discipline in navigating a complex macro environment.
- Process Chromatography and Consumables Carry the Quarter: These segments offset cyclical headwinds and validate Bio-Rad’s strategy of expanding recurring revenue streams.
- Margin Expansion Hinges on Tariff Relief and Cost Discipline: Management’s proactive supply chain moves and cost controls are paying off, but external risks persist.
- Platform Evolution and China Exposure Remain Key Watchpoints: The success of DDPCR launches and Stilla integration, as well as ongoing monitoring of China reimbursement, will be critical for 2026 and beyond.
Conclusion
Bio-Rad’s Q2 2025 results underscore the company’s ability to adapt and execute in a turbulent market. Margin expansion and improved guidance are clear positives, but the outlook remains tethered to the sustainability of process chromatography demand, successful integration of Stilla, and external funding and policy risks. Investors should watch for further progress in portfolio innovation and the resilience of core end markets as the year unfolds.
Industry Read-Through
Bio-Rad’s performance highlights several broader industry themes: Process chromatography demand recovery signals improving biopharma production activity, which could benefit peers with exposure to biologics manufacturing. Digital PCR adoption is accelerating, with platform expansion and workflow simplification driving broader use cases in diagnostics and research. Tariff and supply chain flexibility are emerging as key margin levers for global life science suppliers, underscoring the need for operational agility. Persistent academic and China market headwinds remain a drag across the tools and diagnostics sector, suggesting continued caution for companies with similar exposure.